Clinical–Pathological study of levodopa complications
Identifieur interne : 004535 ( Main/Exploration ); précédent : 004534; suivant : 004536Clinical–Pathological study of levodopa complications
Auteurs : Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-03.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Autopsy, Brain (drug effects), Brain (pathology), Chemotherapy, Complication, Dose-Response Relationship, Drug, Dyskinesia, Exploration, Female, Follow-Up Studies, Human, Humans, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Lewy Bodies (drug effects), Lewy Bodies (pathology), Long term, Male, Middle Aged, Neurologic Examination (drug effects), On off effect, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (pathology), Parkinson disease, Parkinson's disease, Pathology, Symptomatology, Treatment Outcome, dyskinesia, levodopa, on‐off, wearing‐off.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- diagnosis : Parkinson Disease.
- drug effects : Brain, Lewy Bodies, Neurologic Examination.
- drug therapy : Parkinson Disease.
- pathology : Brain, Lewy Bodies, Parkinson Disease.
- Aged, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
We sought to determine the continued benefit and the pattern of motor complications of long‐term levodopa treatment in Parkinson's disease. Patients were evaluated between 1968 and 1996. Only those who had an adequate levodopa trial and in whom autopsy revealed Lewy body Parkinson's disease were included. Total levodopa and mean daily dose were calculated in each case. Dyskinesia, wearing‐off and on‐off were collectively classified as motor adverse effects and reported as cumulative incidence. Forty‐two patients (male, 30; female, 12) with mean 15.9 years of illness and 9.1 years follow‐up received on average 500‐mg levodopa daily over 9.8 years. Seventeen of 21 patients assessed during the last 18 months of life reported some motor benefit. Adverse effects were seen in 71.4% of patients. The most common was dyskinesia, in 61.9%; wearing‐off in 35.7%; and on‐off in 16.7% of patients. The earliest adverse effect was dyskinesia and the last to emerge was on‐off. Isolated dyskinesia was seen in 35.7% and wearing‐off in 7.1% of patients; 15.5% of patients developed dyskinesia after 2.6 years and 31% after 6.4 years on levodopa. We concluded that levodopa benefit declined and adverse effects increased with time. Dyskinesia was the earliest and the most common isolated adverse effect. © 2002 Movement Disorder Society.
Url:
DOI: 10.1002/mds.10031
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000226
- to stream Istex, to step Curation: 000226
- to stream Istex, to step Checkpoint: 002E27
- to stream Main, to step Merge: 006541
- to stream PascalFrancis, to step Corpus: 002794
- to stream PascalFrancis, to step Curation: 000527
- to stream PascalFrancis, to step Checkpoint: 002826
- to stream Main, to step Merge: 006865
- to stream PubMed, to step Corpus: 003B31
- to stream PubMed, to step Curation: 003B31
- to stream PubMed, to step Checkpoint: 003B58
- to stream Ncbi, to step Merge: 000720
- to stream Ncbi, to step Curation: 000720
- to stream Ncbi, to step Checkpoint: 000720
- to stream Main, to step Merge: 006219
- to stream Main, to step Curation: 004535
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical–Pathological study of levodopa complications</title><author><name sortKey="Rajput, Azi H" sort="Rajput, Azi H" uniqKey="Rajput A" first="Azi H." last="Rajput">Azi H. Rajput</name></author><author><name sortKey="Fenton, Mark E" sort="Fenton, Mark E" uniqKey="Fenton M" first="Mark E." last="Fenton">Mark E. Fenton</name></author><author><name sortKey="Birdi, Sam" sort="Birdi, Sam" uniqKey="Birdi S" first="Sam" last="Birdi">Sam Birdi</name></author><author><name sortKey="Macaulay, Rob" sort="Macaulay, Rob" uniqKey="Macaulay R" first="Rob" last="Macaulay">Rob Macaulay</name></author><author><name sortKey="George, David" sort="George, David" uniqKey="George D" first="David" last="George">David George</name></author><author><name sortKey="Rozdilsky, Bohdar" sort="Rozdilsky, Bohdar" uniqKey="Rozdilsky B" first="Bohdar" last="Rozdilsky">Bohdar Rozdilsky</name></author><author><name sortKey="Ang, Lee C" sort="Ang, Lee C" uniqKey="Ang L" first="Lee C." last="Ang">Lee C. Ang</name></author><author><name sortKey="Senthilselvan, Ambikaipakan" sort="Senthilselvan, Ambikaipakan" uniqKey="Senthilselvan A" first="Ambikaipakan" last="Senthilselvan">Ambikaipakan Senthilselvan</name></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1CAB15E36C0187E2EF0A94E4918E56F15C55C00A</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10031</idno><idno type="url">https://api.istex.fr/document/1CAB15E36C0187E2EF0A94E4918E56F15C55C00A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000226</idno><idno type="wicri:Area/Istex/Curation">000226</idno><idno type="wicri:Area/Istex/Checkpoint">002E27</idno><idno type="wicri:doubleKey">0885-3185:2002:Rajput A:clinical:pathological:study</idno><idno type="wicri:Area/Main/Merge">006541</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:02-0309317</idno><idno type="wicri:Area/PascalFrancis/Corpus">002794</idno><idno type="wicri:Area/PascalFrancis/Curation">000527</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002826</idno><idno type="wicri:doubleKey">0885-3185:2002:Rajput A:clinical:pathological:study</idno><idno type="wicri:Area/Main/Merge">006865</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:11921114</idno><idno type="wicri:Area/PubMed/Corpus">003B31</idno><idno type="wicri:Area/PubMed/Curation">003B31</idno><idno type="wicri:Area/PubMed/Checkpoint">003B58</idno><idno type="wicri:Area/Ncbi/Merge">000720</idno><idno type="wicri:Area/Ncbi/Curation">000720</idno><idno type="wicri:Area/Ncbi/Checkpoint">000720</idno><idno type="wicri:doubleKey">0885-3185:2002:Rajput A:clinical:pathological:study</idno><idno type="wicri:Area/Main/Merge">006219</idno><idno type="wicri:Area/Main/Curation">004535</idno><idno type="wicri:Area/Main/Exploration">004535</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clinical–Pathological study of levodopa complications</title><author><name sortKey="Rajput, Azi H" sort="Rajput, Azi H" uniqKey="Rajput A" first="Azi H." last="Rajput">Azi H. Rajput</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea><wicri:noRegion>Saskatchewan</wicri:noRegion></affiliation></author><author><name sortKey="Fenton, Mark E" sort="Fenton, Mark E" uniqKey="Fenton M" first="Mark E." last="Fenton">Mark E. Fenton</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea><wicri:noRegion>Saskatchewan</wicri:noRegion></affiliation></author><author><name sortKey="Birdi, Sam" sort="Birdi, Sam" uniqKey="Birdi S" first="Sam" last="Birdi">Sam Birdi</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea><wicri:noRegion>Saskatchewan</wicri:noRegion></affiliation></author><author><name sortKey="Macaulay, Rob" sort="Macaulay, Rob" uniqKey="Macaulay R" first="Rob" last="Macaulay">Rob Macaulay</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, Dalhousie University, Halifax, Nova Scotia</wicri:regionArea><wicri:noRegion>Nova Scotia</wicri:noRegion></affiliation></author><author><name sortKey="George, David" sort="George, David" uniqKey="George D" first="David" last="George">David George</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neuropathology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea><wicri:noRegion>Saskatchewan</wicri:noRegion></affiliation></author><author><name sortKey="Rozdilsky, Bohdar" sort="Rozdilsky, Bohdar" uniqKey="Rozdilsky B" first="Bohdar" last="Rozdilsky">Bohdar Rozdilsky</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neuropathology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea><wicri:noRegion>Saskatchewan</wicri:noRegion></affiliation></author><author><name sortKey="Ang, Lee C" sort="Ang, Lee C" uniqKey="Ang L" first="Lee C." last="Ang">Lee C. Ang</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Senthilselvan, Ambikaipakan" sort="Senthilselvan, Ambikaipakan" uniqKey="Senthilselvan A" first="Ambikaipakan" last="Senthilselvan">Ambikaipakan Senthilselvan</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Community Health & Epidemiology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea><wicri:noRegion>Saskatchewan</wicri:noRegion></affiliation></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>Brain Research Institute, Vienna University Medical School, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-03">2002-03</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="289">289</biblScope><biblScope unit="page" to="296">296</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1CAB15E36C0187E2EF0A94E4918E56F15C55C00A</idno><idno type="DOI">10.1002/mds.10031</idno><idno type="ArticleID">MDS10031</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antiparkinson agent</term><term>Autopsy</term><term>Brain (drug effects)</term><term>Brain (pathology)</term><term>Chemotherapy</term><term>Complication</term><term>Dose-Response Relationship, Drug</term><term>Dyskinesia</term><term>Exploration</term><term>Female</term><term>Follow-Up Studies</term><term>Human</term><term>Humans</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Lewy Bodies (drug effects)</term><term>Lewy Bodies (pathology)</term><term>Long term</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>On off effect</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (pathology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Pathology</term><term>Symptomatology</term><term>Treatment Outcome</term><term>dyskinesia</term><term>levodopa</term><term>on‐off</term><term>wearing‐off</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term><term>Lewy Bodies</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term><term>Lewy Bodies</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Anatomopathologie</term><term>Antiparkinsonien</term><term>Autopsie</term><term>Chimiothérapie</term><term>Complication</term><term>Dyskinésie</term><term>Effet on off</term><term>Exploration</term><term>Homme</term><term>Long terme</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Symptomatologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We sought to determine the continued benefit and the pattern of motor complications of long‐term levodopa treatment in Parkinson's disease. Patients were evaluated between 1968 and 1996. Only those who had an adequate levodopa trial and in whom autopsy revealed Lewy body Parkinson's disease were included. Total levodopa and mean daily dose were calculated in each case. Dyskinesia, wearing‐off and on‐off were collectively classified as motor adverse effects and reported as cumulative incidence. Forty‐two patients (male, 30; female, 12) with mean 15.9 years of illness and 9.1 years follow‐up received on average 500‐mg levodopa daily over 9.8 years. Seventeen of 21 patients assessed during the last 18 months of life reported some motor benefit. Adverse effects were seen in 71.4% of patients. The most common was dyskinesia, in 61.9%; wearing‐off in 35.7%; and on‐off in 16.7% of patients. The earliest adverse effect was dyskinesia and the last to emerge was on‐off. Isolated dyskinesia was seen in 35.7% and wearing‐off in 7.1% of patients; 15.5% of patients developed dyskinesia after 2.6 years and 31% after 6.4 years on levodopa. We concluded that levodopa benefit declined and adverse effects increased with time. Dyskinesia was the earliest and the most common isolated adverse effect. © 2002 Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Canada</li></country><region><li>Ontario</li><li>Vienne (Autriche)</li></region><settlement><li>Toronto</li><li>Vienne (Autriche)</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Rajput, Azi H" sort="Rajput, Azi H" uniqKey="Rajput A" first="Azi H." last="Rajput">Azi H. Rajput</name></noRegion><name sortKey="Ang, Lee C" sort="Ang, Lee C" uniqKey="Ang L" first="Lee C." last="Ang">Lee C. Ang</name><name sortKey="Birdi, Sam" sort="Birdi, Sam" uniqKey="Birdi S" first="Sam" last="Birdi">Sam Birdi</name><name sortKey="Fenton, Mark E" sort="Fenton, Mark E" uniqKey="Fenton M" first="Mark E." last="Fenton">Mark E. Fenton</name><name sortKey="George, David" sort="George, David" uniqKey="George D" first="David" last="George">David George</name><name sortKey="Macaulay, Rob" sort="Macaulay, Rob" uniqKey="Macaulay R" first="Rob" last="Macaulay">Rob Macaulay</name><name sortKey="Rozdilsky, Bohdar" sort="Rozdilsky, Bohdar" uniqKey="Rozdilsky B" first="Bohdar" last="Rozdilsky">Bohdar Rozdilsky</name><name sortKey="Senthilselvan, Ambikaipakan" sort="Senthilselvan, Ambikaipakan" uniqKey="Senthilselvan A" first="Ambikaipakan" last="Senthilselvan">Ambikaipakan Senthilselvan</name></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004535 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004535 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1CAB15E36C0187E2EF0A94E4918E56F15C55C00A
|texte= Clinical–Pathological study of levodopa complications
}}
| This area was generated with Dilib version V0.6.23. |  |